What did @otpept1de actually say?
The creator rattled off a four-item peptide shopping list in under ten seconds: "take red a true tide" (almost certainly retatrutide) for weight loss, GHK-Cu for better skin, IGF-1 LR3 to build muscle, and BPC-157 with TB-500 to heal injuries. Then signed off with "take me later," which feels like a wink at the peptide community but also neatly sidesteps any medical framing. No dosing, no caveats, no mention that most of these compounds are either unregulated, unapproved, or banned in sport. Just a list.
This is the kind of content that sounds authoritative because it's confident and brief. Four peptides, four goals, done. The problem is that confidence and accuracy are not the same thing, and the regulatory and safety gaps here are substantial.
Does the science back this up?
It depends on which peptide you're looking at. Some of these have real clinical data behind them. Others are running almost entirely on rodent studies and gym-forum anecdotes.
Retatrutide (GLP-1/GIP/glucagon triple agonist) has genuine Phase 2 data. Jastreboff et al. (2023, NEJM) showed mean weight reduction of up to 17.5% over 24 weeks in adults with obesity. That's not nothing. But it's also a compound currently in Phase 3 trials, not approved by the FDA, and not available through legitimate compounding channels the way semaglutide or tirzepatide are.
GHK-Cu has interesting in vitro evidence for collagen synthesis and wound healing, but human RCT data for cosmetic or systemic skin improvement is thin. Pickart and Margolina (2018, Cosmetics) reviewed the mechanistic evidence but acknowledged most findings are preclinical.
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with anabolic properties studied mostly in cell lines and animal models. Human performance data is largely absent from peer-reviewed literature. It carries real hypoglycemia risk.
BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) have animal-model data for tissue repair, but zero completed human RCTs as of mid-2024.
What did they get wrong (or right)?
Credit where it's due: the retatrutide call for weight loss is the most defensible claim in the video. The clinical signal is real, even if the compound isn't approved. GHK-Cu as a skin peptide is at least plausible given its known role in copper-dependent collagen pathways.
Where this falls apart is IGF-1 LR3 for muscle building and the injury stack. Presenting IGF-1 LR3 as a straightforward muscle-building tool ignores that it is a Schedule III-adjacent compound with insulin-mimetic effects. Hypoglycemia is a documented risk. Camperi et al. (2021, Analytical and Bioanalytical Chemistry) flagged it as a common substance in doping control findings, which tells you something about who's actually using it and how it's being sourced.
The BPC-157 and TB-500 injury claim is the weakest. Saying "take" these compounds to heal injuries implies a clinical reliability that simply does not exist in the human literature. Rodriguez et al. (2023, Frontiers in Pharmacology) summarized the state of BPC-157 research and noted that while animal findings are consistent, no human trials have been completed. That gap matters.
What should you actually know?
Most peptides mentioned in this video are not FDA-approved for the stated uses. Several cannot be legally compounded for human use under current FDA guidance. In 2024, the FDA placed BPC-157 on its list of substances that cannot be used in compounding under 503A and 503B. That's a regulatory fact, not an opinion.
Sourcing matters enormously here. Peptides purchased outside of a licensed telehealth or pharmacy pathway have no guaranteed purity, sterility, or accurate concentration. A 2020 analysis by Holt et al. (Drug Testing and Analysis) found significant label inaccuracy in peptides sold through research chemical suppliers.
If you're interested in peptide therapy, that conversation belongs with a licensed provider who can order through a verified compounding pharmacy, review your labs, and monitor for adverse effects. A ten-second TikTok list is not a treatment plan.